The combined application of Anta‐137463 and Anti‐PD‐1 substantially reduced tumor mass, weight, volume, and cholesterol content compared to other groups, suggesting that the greatest decrease in oncogenic burden was achieved by the co‐application of Anta‐137463 and Anti‐PD‐1 (Figure 7B–E). The gene discussed is PDCD1; the disease is neoplasm.